Anaesthesia and intensive care
-
Anaesth Intensive Care · Apr 2005
Recombinant activated factor VIIa use in massive transfusion and coagulopathy unresponsive to conventional therapy.
We report a retrospective analysis of patients admitted to a tertiary intensive care unit who received recombinant activated factor VIIa (rFVIIa) in an effort to control life-threatening haemorrhage and coagulopathy. Data extracted included: demographics, diagnoses and clinical course, dosage of rFVIIa, blood product requirements and coagulation tests prior to and after rFVIIa, pH, base deficit and temperature. During the study period rFVIIa was given to nine patients with refractory coagulopathy in imminent danger of death. ⋯ Reduced requirements for red blood cells, fresh frozen plasma, platelets and cryoprecipitate followed rFVIIa administration in eight cases. One patient died after 48 hours of complications unrelated to the initial pathology. Seven patients were discharged from hospital; one remains in hospital. rFVIIa provided improvement in coagulopathy unresponsive to conventional therapy.
-
Anaesth Intensive Care · Apr 2005
Letter Case ReportsLaryngospasm induced by topical application of lignocaine.
-
Trauma is the leading non-obstetric cause of maternal death. Optimal management of the pregnant trauma patient requires a multidisciplinary approach. The anaesthetist and critical care physician play a pivotal role in the entire continuum of fetomaternal care, from initial assessment, resuscitation and intraoperative management, to postoperative care that often involves critical care support and patient transfer. ⋯ Recognizing and understanding the mechanisms of injury, the factors that may predict fetal outcome, and the pathophysiological changes that can result from trauma, will allow early identification and treatment of fetomaternal injury. This in turn should improve morbidity and mortality. A framework for the acute care of the pregnant trauma patient is presented.
-
Anaesth Intensive Care · Apr 2005
Randomized Controlled Trial Clinical TrialEffect of nitrous oxide in reducing pain of propofol injection in adult patients.
In a randomized, double-blind, prospective trial we compared the efficacy of pre-treatment with nitrous oxide (with or without premixed lignocaine in propofol) for the prevention of propofol-induced pain. Ninety consecutive patients were recruited in the study and divided into three groups of 30 each, who received either 50% nitrous oxide in oxygen along with lignocaine 40 mg mixed in 1% propofol 20 ml (Group NL), 50% nitrous oxide in oxygen without lignocaine in propofol (Group N), and 50% oxygen in air with lignocaine mixed in propofol 40 mg (Group L). Pain scores were graded on a four point verbal rating scale (0-3). ⋯ There was no statistical difference observed between group N and group L. Inhalation of 50% nitrous oxide reduces pain on propofol injection. The combination of 50% nitrous oxide and lignocaine mixed with propofol was the most effective treatment.
-
Serotonin syndrome results from excessive activation of serotonin (5-hydroxytryptamine; 5-HT) receptors in the nervous system, on the surface of platelets, and on the vascular endothelium. The clinical manifestations are a triad of altered conscious state, autonomic dysfunction, and neuromuscular excitability. Clinical diagnostic criteria remain poorly defined and unvalidated, and there are no available investigations to confirm the diagnosis. ⋯ Neuromuscular excitability is likely to be the cause of rhabdomyolysis seen in severe cases and should be treated with benzodiazepines and muscle relaxants. Supportive therapies are required to treat hyperthermia and autonomic dysfunction. Cyproheptadine is the most commonly administered serotonergic antagonist, but is unavailable in parenteral form.